Antitumor effect of combined use of OK-432 and yeast cell wall with mitomycin-C in mice.
Tumor-inhibitory effect of combined use of mitomycin-C and streptococcal preparation (OK-432) or yeast cell wall (YCW) was examined. Twenty-four hours after intraperitoneal inoculation of Ehrlich carcinoma cells, combination therapy was carried out and tumor growth was observed for 40 days. About one-half of mice treated with yeast cell wall at a single dose of 1 mg survived free of tumor. Mitomycin-C at a single dose of 2 microgram was not effective. However, in combination with yeast cell wall, tumor suppression was observed in 70% of the mice. This tumor-inhibitory effect was enhanced by subsequent treatment with OK-432 or yeast cell wall. When these materials were injected separately or in combination with mitomycin-C, the number of peritoneal exudate cells increased about 3 to 6 times after 3 days and these cells exhibited cytotoxic effect on tumor cells. Hemagglutinating antibody to sheep erythrocytes was hardly affected by the combination therapy.
D000818:Animals; D000917:Antibody Formation; D001202:Ascitic Fluid / Q000166:cytology / Q000276:immunology; D001688:Biological Products / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002452:Cell Count; D002473:Cell Wall / Q000276:immunology; D005260:Female; D007167:Immunotherapy; D008297:Male; D051379:Mice; D008937:Mitomycins / Q000494:pharmacology*; D010844:Picibanil / Q000494:pharmacology*; D015003:Yeasts / Q000276:immunology*
D001688:Biological Products; D008937:Mitomycins; D010844:Picibanil